Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | UBE2N | P61088 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | HTR6 | P50406 | 8/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125259 | 0.89 | HTR6 (0.61) | KDM4EUBE2NL3MBTL1HTR6CA2 | |
| SCHEMBL5413550 | 0.89 | KDM4E (0.63) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL22339785 | 0.86 | KDM4E (0.60) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL28528958 | 0.85 | L3MBTL1 (0.61) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL1203288 | 0.84 | KDM4E (0.68) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL3615171 | 0.83 | HTR6 (0.78) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL6089916 | 0.82 | KDM4E (0.59) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL27152273 | 0.81 | KDM4E (0.64) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL4009273 | 0.81 | KDM4E (0.64) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL3615167 | 0.81 | KDM4E (0.68) | KDM4EUBE2NL3MBTL1HTR6ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20200255422-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | KDM4E 1284/4885UBE2N 240/4885L3MBTL1 487/4885 |
| US-20200255422-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | KDM4E 1284/4885UBE2N 240/4885L3MBTL1 487/4885 |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | KDM4E 1284/4885UBE2N 240/4885L3MBTL1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.